1
项与 gp140 Vaccine adjuvanted with MF59C.1(NIAID) 相关的临床试验A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
This is an extension of the HVTN 073/SAAVI 102 study. This study will evaluate the safety and immune response to an HIV envelope protein vaccine boost in people who have previously received the SAAVI DNA-C2 and SAAVI MVA-C vaccines or placebo in the HVTN 073/SAAVI 102 study.
100 项与 gp140 Vaccine adjuvanted with MF59C.1(NIAID) 相关的临床结果
100 项与 gp140 Vaccine adjuvanted with MF59C.1(NIAID) 相关的转化医学
100 项与 gp140 Vaccine adjuvanted with MF59C.1(NIAID) 相关的专利(医药)
100 项与 gp140 Vaccine adjuvanted with MF59C.1(NIAID) 相关的药物交易